171 CLINICAL CONSEQUENCES OF OFF-LABEL REDUCED DOSING OF NOACS IN AF 66. Lobato SM, Tarrazo CT, Fernández EG, Alcalá MM. Clinical profile, adequacy of dosage and thromboembolic and bleeding outcomes in patients with nonvalvular atrial fibrillation treated with rivaroxaban in a regional hospital of Asturias, Spain. Future Cardiol. 2018;14(3s):17–24. 67. Navarro-Almenzar B, Cerezo-Manchado JJ, Caro-Martinez C, García-Candel F, Flores Blanco PJ, Ruiz GE, et al. Real-life behaviour of direct oral anticoagulants in a Spanish cohort with non-valvular atrial fibrillation: refase registry. Curr Med Res Opin. 2019;35(12):2035– 41. 68. Nielsen PB, Skjøth F, Søgaard M, Kjældgaard JN, Lip GY, Larsen TB. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2017;356:j510. 69. Ogawa S, Ikeda T, Kitazono T, Nakagawara J, Minematsu K, Miyamoto S, et al. Present profiles of novel anticoagulant use in Japanese patients with atrial fibrillation: insights from the rivaroxaban postmarketing surveillance registry. J Stroke Cerebrovasc Dis. 2014;23(10):2520–6. 70. Perreault S, Dragomir A, Côté R, Lenglet A, White-Guay B, de Denus S, et al. Comparative effectiveness and safety of high-dose rivaroxaban and apixaban for atrial fibrillation: a propensity score-matched cohort study. Pharmacotherapy. 2021;41(4):379–93. 71. Qian Y, Zhang J, Li J, Weng Z. A retrospective study on the evaluation of the appropriateness of oral anticoagulant therapy for patients with atrial fibrillation. PLoS One. 2021;16(11):e0259199. 72. Raccah BH, Erlichman Y, Pollak A, Matok I, Muszkat M. Prescribing errors with direct oral anticoagulants and their impact on the risk of bleeding in patients with atrial fibrillation. J Cardiovasc Pharmacol Ther. 2021;10742484211019656. 73. Rahme E, Godin R, Nedjar H, Dasgupta K, Tagalakis V. Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: a Canadian retrospective cohort study. Thromb Res. 2021;203:121–30. 74. Ruiz-Ortiz M, Esteve-Pastor MA, Roldán I, Muniz J, Marín F, Anguita M. Prognostic impact of inappropriate doses of direct oral anticoagulants in clinical practice. Rev Esp Cardiol (Engl Ed). 2020;73(4):329–30. 75. Russo V, Bianchi V, Cavallaro C, Vecchione F, De Vivo S, Santangelo L, et al. Efficacy and safety of dabigatran in a ‘real-life’ population at high thromboembolic and hemorrhagic risk: data from MonaldiCare registry. Eur Rev Med Pharmacol Sci. 2015;19(20):3961–7. 76. Sato T, Aizawa Y, Fuse K, Fujita S, Ikeda Y, Kitazawa H, et al. The comparison of inappropriate-low-doses use among 4 direct oral anticoagulants in patients with atrial fibrillation: from the database of a single-center registry. J Stroke Cerebrovasc Dis. 2018;27(11):3280–8. 77. Shrestha S, Baser O, Kwong WJ. Effect of renal function on dosing of non-vitamin K antagonist direct oral anticoagulants among patients with nonvalvular atrial fibrillation. Ann Pharmacother. 2018;52(2):147–53. 78. Staerk L, Gerds T, Lip G, Ozenne B, Bonde A, Lamberts M, et al. Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study. J Intern Med. 2018;283(1):45–55. 79. Sugrue A, Sanborn D, Amin M, Farwati M, Sridhar H, Ahmed A, et al. Inappropriate dosing of direct oral anticoagulants in patients with atrial fibrillation. Am J Cardiol. 2021;144:52–9. 80. Wattanaruengchai P, Nathisuwan S, Rattanavipanon W, Chulavatnatol S, Kongwatcharapong J, Mitsuntisuk P, et al. Prescriber compliance to direct oral anticoagulant labels and impact on outcomes in Thailand. Br J Clin Pharmacol. 2021;87(3):1390–400. 8
RkJQdWJsaXNoZXIy MTk4NDMw